Scilex Holding Co (SCLX) stock
SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30
$0.64−0.61 (-48.80%)
Close on Nov 17, 2026Market cap $5.44MP/E –Yield –
Scilex revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Scilex's revenue for the twelve months ending Jun 30, 2026 was $31.61M, down 28.5% year over year. For fiscal 2025 it was $30.25M, down 46.5% from the year before. The highest annual figure on record is $56.59M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.25M | -46.5% |
| FY2024 | Dec 31, 2024 | $56.59M | +21.1% |
| FY2023 | Dec 31, 2023 | $46.74M | +22.9% |
| FY2022 | Dec 31, 2022 | $38.03M | +21.4% |
| FY2021 | Dec 31, 2021 | $31.32M | +32.9% |
| FY2020 | Dec 31, 2020 | $23.56M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.64M | -22.8% |
| Q1 FY2026 | Mar 31, 2026 | $8.61M | +72.1% |
| Q4 FY2025 | Dec 31, 2025 | $4.79M | -67.8% |
| Q3 FY2025 | Sep 30, 2025 | $10.56M | -26.8% |
| Q2 FY2025 | Jun 30, 2025 | $9.90M | -39.5% |
| Q1 FY2025 | Mar 31, 2025 | $5.00M | -54.0% |
| Q4 FY2024 | Dec 31, 2024 | $14.90M | +10.7% |
| Q3 FY2024 | Sep 30, 2024 | $14.44M | +42.7% |
| Q2 FY2024 | Jun 30, 2024 | $16.37M | +30.1% |
| Q1 FY2024 | Mar 31, 2024 | $10.88M | +2.9% |
| Q4 FY2023 | Dec 31, 2023 | $13.46M | +12.9% |
| Q3 FY2023 | Sep 30, 2023 | $10.12M | -11.1% |
| Q2 FY2023 | Jun 30, 2023 | $12.58M | +58.7% |
| Q1 FY2023 | Mar 31, 2023 | $10.58M | +55.3% |
| Q4 FY2022 | Dec 31, 2022 | $11.92M | – |
| Q3 FY2022 | Sep 30, 2022 | $11.38M | – |
| Q2 FY2022 | Jun 30, 2022 | $7.93M | – |
| Q1 FY2022 | Mar 31, 2022 | $6.81M | – |
See a number that looks wrong?